Research/art/teacher profile of a person
Name and surname:
MUDr. Bela Mriňáková, PhD., MPH, MHA
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Mrinakova
I.2 - Name
Bela
I.3 - Degrees
MUDr., PhD., MPH, MHA
I.4 - Year of birth
1982
I.5 - Name of the workplace
1st. Department of Oncology Comenius University in Bratislava and OUSA
I.6 - Address of the workplace
Heydukova 10, 812 50 Bratislava
I.7 - Position
assistant lecturer
I.8 - E-mail address
bela.mrinakova@fmed.uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/27342
I.10 - Name of the study field in which a person works at the university
Oncology
I.11 - ORCID iD
0000-0001-9795-0640

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine, Bratislava
II.b - Year
2006
II.c - Study field and programme
General Medicine
II.3 - Third degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine, Bratislava
II.b - Year
2012
II.c - Study field and programme
Oncology
II.4 - Associate professor
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
Assistant lecturer 1st. Department of Oncology Comenius University in Bratislava and OUSA 2017- current
physician, medical oncologist St. Elisabeth Cancer Institute 2006- current
Therapeutic Use Exemption Committee Head Slovak Antidoping Agency 2014- current

IV. - Development of pedagogical, professional, language, digital and other skills

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Oncological propedeutics General Medicine IV General Medicine
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.b - Diploma (second degree)
4
V.4.2 - Number of defended theses
V.4.b - Diploma (second degree)
6
V.5 - Overview of other courses taught in the current academic year according to study programmes

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
69
VI.1.b - Over the last six years
50
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
31
VI.1.b - Over the last six years
20
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
156
VI.1.b - Over the last six years
125
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
127
VI.1.b - Over the last six years
103
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
41
VI.1.b - Over the last six years
29
VI.2 - The most significant research/artistic/other outputs
1

Lambertini, Matteo et al. “Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.” JAMA vol. 331,1 (2024): 49-59. (IF 120.7; Q1)

2

Tankova T, Senkus E, Beloyartseva M, et al. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers (Basel). 2022;14(7):1598. (IF 5.2; Q1)

3

Rubovszky G, et al. Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer [published correction appears in Pathol Oncol Res. 2023 Jan 31;29:1610954]. Pathol Oncol Res. 2022;28:1610383.  (IF 2.8; Q2)

4

Mriňáková, Bela: Reintegration into the workplace In: ESMO handbook of cancer diagnosis & treatment evaluation. - New York : European Society for Medical Oncology, 2020. - S. 109-113.

5

Mrinakova, B. et al.: Improving safety and convenience for breast cancer patients receiving CDK 4/6 inhibitor treatment via a telemedicine app. Annals of Oncology, Volume 34, S365.  (IF 50.5; Q1)

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Lambertini, Matteo et al. “Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.” JAMA vol. 331,1 (2024): 49-59. (IF 120.7; Q1)

2

Tankova T, et al. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers (Basel). 2022;14(7):1598. (IF 5.2; Q1)

3

Rubovszky G, et al. Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer [published correction appears in Pathol Oncol Res. 2023 Jan 31;29:1610954]. Pathol Oncol Res. 2022;28:1610383.  (IF 2.8; Q2)

4

Mriňáková, Bela: Reintegration into the workplace In: ESMO handbook of cancer diagnosis & treatment evaluation. - New York : European Society for Medical Oncology, 2020. - S. 109-113.

5

Mrinakova, B. et al.: Improving safety and convenience for breast cancer patients receiving CDK 4/6 inhibitor treatment via a telemedicine app. Annals of Oncology, Volume 34, S365.  (IF 50.5; Q1)

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Arecco L, Bruzzone M, Bas R, et al. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers. Ann Oncol. 2024;35(9):792-804. (IF 56.7; Q1)

2

Azim HA Jr, Niman SM, Partridge AH, et al. Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy. J Clin Oncol. 2024;42(23):2822-2832. (IF 42.1; Q1)

3

Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Cancer Discov. 2024;14(2):240-257. (IF 29.1; Q1)

4

Helgadottir H, Matikas A, Fernebro J, Frödin JE, Ekman S, Rodriguez-Wallberg KA. Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors. Eur J Cancer. 2024;202:114010. (IF 8.4; Q1)

5

Bajpai R, Bajpai J. Closing the research gaps in obstetric health for survivors of cancer. Lancet Oncol. 2024;25(8):953-955.  (IF 41.6; Q1)

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

sub-investigator: Scientific grant agency of the Ministry of Education, Science, Research and Sports of the Slovak Republic

VEGA 1/0738/21: Complex management of patients in long-term remission after curative treatment of breast cancer and gynecological malignancies.

2

sub-investigator: Scientific Grant Agency of the Ministry of Education, Science, Research and Sports of the Slovak Republic

VEGA 1/0395/21: Development of xenograft models from patient tissues and their use to personalize the treatment of malignant uveal melanoma.

3

sub-investigator: Agency for Research and Development Support

APVV‑22‑023: Therapeutic potential of stress-reducing intervention in complex oncology care.

4

principal investigator: EMBER-4; NCT05514054

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence.


5

principal investigator: A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
Institute Jules Bordet Brussels, Belgium 2009 ESMO Clinical Fellowship u Prof. Martine Piccart-Gebhart
OPEN CEEiling, CEE Young Oncologist Leadership Program CECOG 2021 Prof. Christoph Zielinski

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

Slovak Medical Chamber - member

Slovak Oncological Society - member

Slovak chemotherapeutic society - member

Association of Slovak doctors in Bratislava - member

European Society for Medical Oncology - ESMO - member

American Society of Clinical Oncology- member

ASCO CEE Regional Council- member, deputy of SR

Open Medical Club (Open Medical Club) - member

Open Medical Institute - member

Slovak Antidoping Agency - Chairman of the Therapeutic Exemptions Use Committee

Analytical Gem 2024 - Co-holder of the Award

Editorial office of the journal Klinická onkologie - Prize for the best case report published in 2016

Date of last update
2025-03-31